Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Hoping so....... Lost $6000 after loading up @ $21.70
Falling knife
why? this stock was $3 just two years ago. it can fall just as fast as it can go up, sometimes, much faster.
i have no position here, but I have been following this stock for a LONG TIME
wonder if this was on Einhorn's list?
Cramer made a great point, medicaid is way more rigorous than INS. Co. Standards. If Medicaid is paying up we should expect aetna to pay up too. I fully expect a favorable resolution regarding coverage.
Conferece call was great.
They basically said that Aetna made the decision based off of old data.
Anyways, looks like a number of people liked what they heard and the stock is going back up.
Should be an interesting afternoon.
Nice dude. Good trade. Did you cover yet?
Aetna is taking the business side of a health problem and saying that if you have MS and typical treatments don't work, better buy your tombstone because we aren't going to pay for other treatments.
Take a look at what Questcor says about the group of patients for which this product is for.
They never really said that the product was going to save people with MS.
It is for those which have usually tried known treatment, but had less than stellar results.
Sure this in and of itslef isn't a glowing review for the product, but let's say you have a disease and go through the typical treatment. Unfortunately the treatment doesn't take for you. What do you do at this time? Accept Death?
Now, if the company marketed the product as the best thing in the world for MS patients, than I would totally agree with your assessment of where the stock is headed.
Nasdaq actually says $47.33 is the after hours high.
If someone put a market order and got that I guess they might not do that 423 Shares ....
$20 loss per share (for now).
Man, I used to utilize a brokerage called Questrade ... if that happened there you would see the buy at the regular market (say 27.xx) and then the sale to you (at $47.33). Needless to say, I don't use them anymore.
I never had anything that bad (maybe like 0.10 or whatever), but how can I trust them when they do that?
LOL, with sub-penny stocks (OTC/Pinks) we are talking like 20% of the trade. If I want to sell, someone better be willing to pay 20% more than what my order says ....
You are forgetting something. The rest of the insurance companies that are beginning their Due Diligence right now as a result of Aetna's actions ..
$QCOR single digits by EOY ~
Good luck
I do feel for the longs here and the only suggestion I can give is to buy some put protection on the next bounce ..
This is a Bio-Pharma and this type of insurance news crushes them all the time
IE : Denderon
Thats just the MM's settling shares .. you can grab a nice sale of shares if you can catch it or set sell orders in after hours .. 1/100 it takes.
I think everyone way over reacted, this should not have dropped like this. I think the drop set off sell triggers and then pushed it way down. Thinking this will have a good bounce tomorrow , I hope..
During 2012, Aetna has accounted for approximately 5% of the Company's shipped prescriptions for Acthar.
Oversold or game over .. time will tell..
Thanks for both of ur replies. I am thinking about getting in as a long term option; it's speculative right now.. It could go either way tomorrow morning.. Didn't buy today but if it goes down tomorrow then I may jump in. Anyone think it will come back up or stay down?
I meant to say "very rarely does anything happen"
No divs. Anytime a stock drops this hard there is an attorney investigating. Very rarely doesn't anything ever happen.
The price flashed as over $36 in after hours ....
Seemed odd to me.
Anyone know what that could be about?
I mean was that the average price?
I don't know, it could fall more tomorrow... it's a gamble. As far as law firms, there will be a dozen law firms going for free advertising by the end of the week.
Would you say this is a good buy for mid term? Do they give any dividends?
Also read about law firm Wohl and Fruchter announcing investigation.. Drop further?
So trading resumes at 3:PM ET ?
The company released a statement saying that Aetna only accounted for about 5% of Acthar sales.
opens in 19 minutes
Yup, thinking halted for the day now. Maybe news after hours or pre market tomorrow.
This halt is long. An hour?
Another halt... possibly company news release pending.
I bought 1500 shares in 500 increments, average $29.60 and sold in 500 increments average $33.60.
I was panicking for a bit though because it was dropping fast and hard and I was down a lot.
Wild swings!
Excellent trade!
23 to 33 not bad
MK
Made $4.5 G in about 3 minutes, could have played it twice.. but didn't. This thing is all over the map.
Questcor Pharmaceuticals Inc. (QCOR) shares plunged Wednesday after insurer Aetna Inc. (AET) limited reimbursement of the pharmaceutical company's only drug, Acthar, for treatment of infantile spasms.
Shares recently dropped 40% to $30.05 on heavy volume and earlier hit a 52- week low of $22.26 as Aetna called the drug medically unnecessary to treat certain other conditions.
Noted short-seller Citron Research highlighted a policy bulletin on Aetna's website from Friday that called Acthar medically necessary for West syndrome, a relatively rare neurological disorder that causes infantile spasms, but described its use for several other conditions as medically unnecessary, or investigational and experimental.
Representatives from Questcor weren't immediately available for comment.
An Aetna spokeswoman told Dow Jones the decision was based on the lack of clinical evidence that the drug is more effective than steroids, adding its position is based on an analysis of the available data and is supported by public statements from the chief medical officer of the National Multiple Sclerosis Society . It will review the policy based on any new clinical data on Oct. 13 .
In 2010, the U.S. Food and Drug Administration updated its approval of Acthar to cover 19 different indications, narrowing the company's immediate focus for growth to patients suffering from kidney-related disorders.
Questcor originally sold the drug to address infantile spasms, but now markets the compound for multiple sclerosis flare-ups and is funding an exploratory study for patients whose kidney problems are caused by diabetes, opening the company up to a potentially massive market. Treatments for kidney-related disorders seem to represent the next frontier for the drug.
Potential future uses include treatment for proteinuria among diabetics, lupus and rheumatic diseases.
Write to Anna Prior at anna.prior@dowjones.com
Trading resumed. Bouncing off low 22.
Ouch!
Back to 2 months ago, maybe heading down to 1 year price.
Covered in a bit more detail, here:
http://www.siliconinvestor.com/readmsg.aspx?msgid=28382572
BoA aiming for $60-64 PO target.
This is on the back of the better Medicaid rebate amount in favor for the company, a possible 76% change!
3-6 months down the line for change to have effect.
I am still long on this. the big drop was due to the manipulation of the stock through the pr from that short research firm and the shorts covering their positions. As of 6/29, 26.6% was held short. Love to see the short position now after the manipulated plunge in shares. I agree that the quarterly numbers should look good and earnings will hopefully beat expectations.
IMO, QCOR has answered the questioned about how easy it may be to make a generic version of their drug. Until such time another company actually comes out with and proves that their generic version works as well, QCOR is the market here.
QCOR's entire sales teams will finally be out on the street the end of the summer and with all the feet on the ground (IMO) QCOR's sales will continue to rise for the next several quarters. Regardless of the current or six month outlook in the Domestic or Foreign Economic conditions, QCOR will be selling their drug because it works and doctors are prescribing it.
I have used the Raid to load up once again, and for that I say thank you !!
Earnings due on the 26th, good luck to all,
GW323.
the "research" was from a short sell research firm and they achieved what they intended with the fall in share price. this stock has been shorted like crazy and the purpose of the release had been accomplished. earnings should be up and hopefully above the estimates would be great to see the high 50s again.
Excellent buying opportunity here too. Earnings will be very nice ad usual although I am concerned management of Bailey and Co hasn't replied yet.
Another Streetsweeper rumor going around.
Maybe a good time to buy on the dip!
Let's see if we can close over the 44 mark. That would set us up nicely for next week. No real overhead above that point , could see a nice move north for awhile.
GLTA
GW323
I stated to 'nevermind' and remove my message, lol.
Don't know what you're saying. You can find the note plenty of places. Here's another one:
http://www.benzinga.com/analyst-ratings/analyst-color/12/04/2527599/update-jefferies-raises-pt-to-52-on-questcor-pharmaceuti
UPDATE: Jefferies Raises PT to $52 on Questcor Pharmaceuticals; Solid Q1 Beat
By David Johnson
Benzinga Staff Writer
April 25, 2012 9:23 Symbols: QCOR
Followers
|
24
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
407
|
Created
|
04/30/09
|
Type
|
Free
|
Moderators |
At Questcor, we are a biopharmaceutical company whose products help patients with serious, difficult-to-treat medical conditions. Our efforts are currently focused on the fields of neurology and nephrology, areas of medicine which have significant unmet medical needs.
Our highly experienced Sales and Marketing teams are presently focused on increasing the usage of our primary marketed product, Acthar, among specialists who treat patients with multiple sclerosis, infantile spasms and nephrotic syndrome. In addition, our Medical Affairs personnel are working with leading researchers to explore promising additional uses for this important product in a variety of other conditions.
How we implement our business strategy:
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |